Phase I Comparative Bioavailability Study

Exclusion Criteria

• - Patients receiving chemotherapy, radiotherapy (except for palliative reasons) or any other anti-cancer therapy within 4 weeks of the last dose prior to study entry. Patients may continue the use of biphosphonates for bone metastases and corticosteroids
• - Patients with symptomatic uncontrolled brain metastases
• - Major surgery within 2 weeks of starting study and patients must have recovered from any effects of any major surgery
• - Patients who are platinum refractory (Group 8 only)
• - Patients with myelodysplastic syndrome/acute myeloid leukaemia (Group 8 only).